{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:19:27Z","timestamp":1757618367995,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00059-025-05322-0","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:01:20Z","timestamp":1750071680000},"page":"229-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular risk reduction in patients with diabetes mellitus and\/or chronic kidney disease\u2014an update","Kardiovaskul\u00e4re Risikoreduktion bei Patienten mit Diabetes mellitus und\/oder chronischer Nierenerkrankung\u00a0\u2013 ein Update"],"prefix":"10.1007","volume":"50","author":[{"given":"Katharina","family":"Marx-Sch\u00fctt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"5322_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman\u00a0RR, Paul\u00a0SK, Bethel\u00a0MA (2008) 10-year follow-up of intensive glucose control in type\u00a02 diabetes. N\u00a0Engl J Med 359:1577\u20131589","journal-title":"N Engl J Med"},{"key":"5322_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","volume":"5","author":"S Zoungas","year":"2017","unstructured":"Zoungas\u00a0S, Arima\u00a0H, Gerstein\u00a0HC (2017) Effects of intensive glucose control on microvascular outcomes in patients with type\u00a02 diabetes: a\u00a0meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5:431\u2013437","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5322_CR3","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx\u00a0N, Federici\u00a0M, Sch\u00fctt\u00a0K (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart\u00a0J 44:4043\u20134140","journal-title":"Eur Heart J"},{"key":"5322_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, Tuttle\u00a0KR, Rossing\u00a0P (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med 391:109\u2013121","journal-title":"N Engl J Med"},{"key":"5322_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","author":"RE Pratley","year":"2024","unstructured":"Pratley\u00a0RE, Tuttle\u00a0KR, Rossing\u00a0P (2024) Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.004","journal-title":"J Am Coll Cardiol"},{"key":"5322_CR6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, Petrie\u00a0MC, Borlaug\u00a0BA (2024) Semaglutide in Patients with Obesity-Related Heart Failure and Type\u00a02 Diabetes. N\u00a0Engl J Med 390:1394\u20131407","journal-title":"N Engl J Med"},{"key":"5322_CR7","doi-asserted-by":"publisher","DOI":"10.1714\/4361.43518","author":"JW McEvoy","year":"2024","unstructured":"McEvoy\u00a0JW, Mccarthy\u00a0CP, Bruno\u00a0RM (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart\u00a0J. https:\/\/doi.org\/10.1714\/4361.43518","journal-title":"Eur Heart J"},{"key":"5322_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi\u00a0Y, Li\u00a0M, Liu\u00a0Y (2025) Intensive Blood-Pressure Control in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med 392:1155\u20131167","journal-title":"N Engl J Med"},{"key":"5322_CR9","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen\u00a0BL, Fletcher\u00a0RA, Heath\u00a0L (2024) Cardiovascular, Kidney, and Safety Outcomes With GLP\u20111 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type\u00a02 Diabetes: A\u00a0Systematic Review and Meta-Analysis. Circulation 150:1781\u20131790","journal-title":"Circulation"},{"key":"5322_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo\u00a0EM, Neuen\u00a0BL, Fletcher\u00a0RA (2024) Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a\u00a0SMART\u2011C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 12:545\u2013557","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5322_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","author":"DK Mcguire","year":"2025","unstructured":"Mcguire\u00a0DK, Marx\u00a0N, Mulvagh\u00a0SL (2025) Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type\u00a02 Diabetes. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"key":"5322_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.074545","author":"N Marx","year":"2025","unstructured":"Marx\u00a0N, Deanfield\u00a0JE, Mann\u00a0JFE (2025) Oral Semaglutide and Cardiovascular Outcomes in Persons With Type\u00a02 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074545","journal-title":"Circulation"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05322-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05322-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05322-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:44:37Z","timestamp":1757187877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-025-05322-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5322"],"URL":"https:\/\/doi.org\/10.1007\/s00059-025-05322-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"9 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.\u00a0Marx-Sch\u00fctt has received personal fees for lectures from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Novartis, OmniaMed and served as an advisor for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}